This page contains an index to all policies of the Colorado Medical Society. The title of each major section is a clickable link to the related policies.


145. Drug Abuse

145.992 Marijuana

  • CMS recognizes the potential health benefits and adverse health effects of marijuana (cannabis) and supports the education of its members regarding these issues.
  • CMS opposes the inhalation of smoke from any substance, including cannabis.
  • CMS opposes people self-diagnosing and treating themselves or family members with cannabis, especially children.
  • CMS recommends that patients being treated for a particular medical condition with cannabis be under the care of a physician, and if necessary, in consultation with a physician with specialty training in the condition for which the patient seeks care.
  • CMS supports increased efforts and funding directed at education, prevention and treatment of substance use disorders, particularly cannabis use disorder.
  • CMS supports increased state and federal funding for cannabis research, easing regulatory restrictions impeding approval for cannabis and cannabinoid research, and encouraging ongoing collection of individual and population data on patients using cannabis.
  • CMS supports rescheduling cannabis from a Schedule I to a Schedule II drug to enable clinical research and requirements regarding standardization and prescribing guidelines of cannabinoids congruent with the FDA drug development process.
  • CMS supports further pharmacologic research to develop potency limits for cannabis.
  • CMS supports the identification, monitoring and publicizing of results of health care and social costs associated with cannabis use.
  • In regard to this issue, CMS endorses enforcement of current state law, regulations and guidelines including having a bona fide patient-physician relationship and maintaining medical records that are readily accessible.
  • CMS supports improved efforts on cannabis product testing and regulation. In addition, CMS supports informing the public about contaminated cannabis products to protect Coloradans.
  • (BOD Nov. 15, 2018)

    145.993 Supervised consumption services to combat opioid overdose deaths

    Colorado Medical Society supports the establishment of a pilot supervised injection facility that will be objectively evaluated to assess effects on those that are addicted to injectable drugs, local communities and society at large as part of a comprehensive strategy to combat the effects of the opioid abuse crisis in Colorado.

    (Board action, Sept. 15, 2017)

    145.994 Public Health and Safety Challenges of Treating Chronic Pain: The Medical Perspective

    The Colorado Medical Society Workers’ Compensation and Personal Injury Committee (WCPIC) were asked by the board to review current CMS policy on prescription drug abuse and make strategic recommendations for moving forward. WCPIC created the platform “Public Health and Safety Challenges of Treating Chronic Pain: The Medical Perspective,” which encompasses 31 recommendations. It was presented to and passed by the CMS House of Delegates at the 2013 Annual Meeting in September.

    The platform focuses on five planks: the Prescription Drug Monitoring Program (PDMP), licensing boards standardization, physician education, law enforcement, and prescription drug abuse as a public health issue. Click here to view the 31 recommendations.

    Formerly Policy 155.992
    (BOD-1, AM 2013; Reaffirmed, BOD-1, AM 2014)

    145.995 Recreational Marijuana

    CMS does not have an opinion on the criminality of recreational marijuana use. CMS recognizes the published scientific data that recreational use of marijuana has a deleterious effect on the health of individuals and public health, particularly on the developing brains of adolescents.
    (RES 6-P-AM’11, AM 2012; Reaffirmed, BOD-1, AM 2014)

    145.996 Physician Leadership on National Drug Policy

    The Colorado Medical Society (CMS) adopts and supports the consensus statement on “Physician Leadership on National Drug Policy.” The CMS supports the continual review of evidence to identify and recommend medical and public health approaches that are likely to be more cost-effective, in both human and economic terms. The CMS encourages professional organizations to endorse and implement these policies.

    Additional Information: Physician Leadership on National Drug Policy
    (RES-14, AM 1999; Reaffirmed, BOD-1, AM 2014)

    145.997 Drug Abuse and Drug Testing in Youth Athletics

    The Colorado Medical Society (CMS) supports educational activities at the elementary school through high school level on drug abuse in athletes; the CMS supports drug testing for anabolic steroids of middle school and high school athletes in competitive sports.
    (RES-39, AM 1989; Reaffirmed, BOD-1, AM 2014)

    145.998 Use of Anabolic Steroids

    The Colorado Medical Society (CMS) considers the prescription, recommendation, or use of anabolic steroids for the purpose of the hormonal manipulation of athletes that is intended as a performance aid for athletes to increase muscle mass, strength, or weight manipulation without a medical necessity to do so to be unethical and reason for immediate action by the Council on Ethical and Judicial Affairs of the CMS and prompt reporting to the Colorado Medical Board.

    Formerly Policy 155.998
    (RES-40, AM 1987; Revised, BOD-1, AM 2014)

    145.999 Prevention of Abuse and Diversion of Prescription Drugs

    (RES-27, AM 1986; Sunset, BOD-1, AM 2014)